Matinas BioPharma
MTNB
28 hedge funds and large institutions have $618K invested in Matinas BioPharma in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 1 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
143% more capital invested
Capital invested by funds: $254K → $618K (+$364K)
17% more funds holding
Funds holding: 24 → 28 (+4)
1.06% more ownership
Funds ownership: 5.43% → 6.49% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$32.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$18.1K |
| 3 |
HF
HRT Financial
New York
|
+$15.5K |
| 4 |
Renaissance Technologies
New York
|
+$5.17K |
| 5 |
Citigroup
New York
|
+$1.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James Financial
St Petersburg,
Florida
|
-$285 |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SS
26
SBI Securities
Tokyo,
Japan
| $21 | – | – | – |
|
27
Fidelity Investments
Boston,
Massachusetts
| $9 | +$4 | +3 | +150% |
|
|
MCM
28
MAI Capital Management
Independence,
Ohio
| $4 | – | – | – |
|
|
29
Raymond James Financial
St Petersburg,
Florida
| – | -$285 | -320 | Closed |
|
MTNB Hedge Fund Activity: Q3 2025 in Review
28 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2025, worth a combined $618K — up 143% from $254K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MTNB positions and 1 closed out — a net gain of 4 holders — while 8 added to existing stakes and 1 trimmed.
The largest buyer was Northern Trust, opening a new position worth an estimated $32.5K. The largest seller was Raymond James Financial, exiting entirely with an estimated $285 sold.
- 28 institutional investors held Matinas BioPharma (MTNB) as of Q3 2025, up from 24 in Q2 2025.
- Funds reported $618K of Matinas BioPharma stock for Q3 2025, up 143% quarter-over-quarter.
- 5 funds opened new Matinas BioPharma positions in Q3 2025 and 1 closed out, a net change of +4 holders.
- The largest Matinas BioPharma buyer in Q3 2025 was Northern Trust, an estimated $32.5K added.
- The largest Matinas BioPharma seller in Q3 2025 was Raymond James Financial, an estimated $285 sold.
Based on aggregated 13F filings for Q3 2025.